Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies
Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is...
A fresh start for advanced therapy clinical trials
A look at 2020 and the coming rebound, by the numbers Even before the unpredictable year that was 2020, one...
A true platform is the engine for advanced therapies
A Vineti technology perspective from Chief Technology Officer Phil Calvin Phil Calvin, Vineti’s Chief Technology Officer, is a long-time leader...
Now is the time for proven technology that drives scale
A Vineti technology perspective from CEO and Co-founder Amy DuRoss The underlying medical science behind cell and gene therapies continues...
Q&A with Dr. Mike Pellini: the need for advanced software to scale cell and gene therapies
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former...
Design for personalized therapies: reframing “delight” as the goal
Sometimes, in the world of UX and product design, “delight” means getting out of the way. Read about general approaches...
The road ahead for #regenmed
This fall, it will be 15 years since regenerative medicine faced a crisis of funding and support in the United...
ISCT 2019: data elements in the cell therapy value chain
I just got back from speaking at the International Society for Cell Therapy annual meeting, where the topic was next-gen data management....
Cell therapy and gene therapy versus cancer: 10 numbers to watch
ASCO 2019 is here! In 2018, ASCO named CAR-T cell therapy the cancer Advance of the Year, and this year’s ASCO brings more cell...